Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rockwell Medical has started patient recruitment in a Phase III CRUISE-1 study evaluating SFP iron deficiency anemia in hemodialysis dependent-chronic kidney disease patients receiving erythropoietin.
Subscribe to our email newsletter
The company is organizing two pivotal prospective, randomized, double-blinded, placebo-controlled, multicenter study Phase III trials CRUISE-1 and CRUISE-2.
Each study expects to recruit around 300 patients, randomized equally between SFP and placebo groups with a treatment period of up to 12 months.
The primary efficacy end-point for both studies is the mean change in hemoglobin from baseline.
Rockwell chairman and CEO Robert Chioini said enrolling patients in CRUISE-1 in the first quarter of 2011 keeps their clinical development timeline for SFP on target.